TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01739920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: Povidone iodine 5% drop will be instilled into conjunctival sac.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: 1 drop of saline solution 0.9% will be instilled into conjunctival sac.
Study: NCT01785810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
Study: NCT03522493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yaalom Katom
Description: Full face Gas mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yaalom Katom
Description: Full face Gas mask
Study: NCT01310816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI-926
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: oral placebo
Study: NCT00955292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quarfloxin
Description: Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
Study: NCT03902782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intercostal block
Description: Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ESP block
Description: As described earlier

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intercostal block
Description: As described earlier
Study: NCT03528785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid
Description: * Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle
Study: NCT05542979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-003 injection
Description: HH-003 injection is administrated via I.V. infusion
Study: NCT03902782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: As described earlier

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine-epinephrine
Description: As described earlier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: As described earlier
Study: NCT05542979

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administrated via I.V. infusion
Study: NCT02596386

Intervention type: PROCEDURE
Intervention: sialometry
Description: potassium evaluation

Intervention type: PROCEDURE
Intervention: blood test
Description: potassium evaluation
Study: NCT01348984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal fentanyl patch
Description: TFP = transdermal fentanyl patch (50 microgram/hour)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: group 2 = placebo patch
Study: NCT01723631

Intervention type: DEVICE
Group type: OTHER
Intervention: Trap Myelin Test

Intervention type: DEVICE
Group type: OTHER
Intervention: Trap Myelin Test
Study: NCT03189732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin local in AT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT00692224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc gluconate
Description: zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
Study: NCT03013452

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oPEP
Description: Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
Study: NCT03902782

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone injection
Description: As described earlier
Study: NCT03013452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage
Description: Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
Study: NCT03902782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: As described earlier

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: As described earlier
Study: NCT04253834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer
Description: The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GO2 Mouthpiece
Description: The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
Study: NCT01897532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tablets
Study: NCT02502344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle
Description: food control and intensive exercise to lose weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: use metformin to reduce insulin resistance
Study: NCT03238313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plan A

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Toxic Life Cycle of a Cigarette
Description: Video
Study: NCT02095171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX002

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00692224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
Study: NCT00832221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEROQUEL XR (quetiapine)
Description: repeated dose of oral tablets, 8 times per subject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEROQUEL IR (quetiapine)
Description: repeated dose of oral tablets, 4 times per subject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: radioligand [11C]raclopride
Description: single dose of iv admin, 5 times per subject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: radioligand [11C]raclopride
Description: single dose of iv admin, 5 times per subject
Study: NCT02615171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity
Description: The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity
Description: Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
Study: NCT01713426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza
Description: Cutaneous patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Oral capsule
Study: NCT01824134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Klean & Klear The Dandy Day Corp

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Skin Gel Herbal Answers, Inc
Study: NCT02834806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNIR Ridaforolimus Eluting Coronary Stent System
Description: BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
Study: NCT03525418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells
Description: Allogeneic bone marrow-derived mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells
Description: Allogeneic bone marrow-derived mesenchymal stem cell
Study: NCT02139124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 100 mg
Description: Oral 100 mg capsule - active
Study: NCT03022474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Intervention
Description: The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
Study: NCT01940497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
Study: NCT03092739

Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 Immunocytochemistry (ICC)
Description: PD-L1 expression in the cytological specimens will be assessed using different antibodies.
Study: NCT01897532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study: NCT04082130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (XCM)+(CAF)
Description: The description of this intervention has been already given before.
Study: NCT03092739

Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 Immunohistochemistry (IHC)
Description: PD-L1 expression in the histological specimens will be assessed using different antibodies.
Study: NCT04277871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscles training (PFMT) combined with yoga
Description: All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscles training (PFMT) combined with yoga
Description: All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
Study: NCT03162588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
Study: NCT01372592

Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients will receive standard of care surgical treatment dependent on his/her spinal condition.

Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients will receive standard of care surgical treatment dependent on his/her spinal condition.

Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
Study: NCT03593603

Intervention type: DEVICE
Intervention: Nellcor™ Bedside Respiratory Monitoring System
Description: Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
Study: NCT04082130

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (SCTG)+(CAF)
Description: The description of this intervention has been already given before.
Study: NCT03261921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
Study: NCT04279457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DyeVert Plus System
Description: The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized hydration protocol
Description: hydration protocol based up on the Poseidon protocol
Study: NCT04084431

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSC
Description: optimal supportive Care (OSC) alone
Study: NCT01943916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio OA/US (US and OA/US)
Description: opto-acoustic plus gray scale ultrasound
Study: NCT02500160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific instrumentation (MRI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific instrumentation (CT)
Study: NCT04624646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discontinuous monitoring
Description: Discontinuous ECG monitoring by finger contact every day
Study: NCT03456960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438ASA
Description: TAK-438ASA tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438ASA
Description: TAK-438ASA tablet.
Study: NCT01943916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio gray scale ultrasound
Description: gray scale ultrasound alone
Study: NCT03663036

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the shoulder
Description: Clinical and radiological assessments of the shoulders and the donor sites
Study: NCT03456960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438ASA
Description: TAK-438ASA tablet.
Study: NCT01634516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary support
Description: Face to face intervention plus subsequent telephone support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No dietary support
Description: No face to face intervention or subsequent telephone support
Study: NCT04487431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BAY1817080
Description: Oral single dose
Study: NCT02972944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment
Study: NCT04624646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous single-lead ECG Patch
Description: Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour Holter monitoring
Description: Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
Study: NCT02902471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced oscillations measure
Study: NCT03456960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438ASA
Description: TAK-438ASA tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438ASA
Description: TAK-438ASA tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin enteric-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin enteric-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin enteric-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin enteric-coated tablet.
Study: NCT04130828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: Ferrous fumarate 200 mg PO PC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Fumarate
Description: Ferrous fumarate 200 mg PO PC
Study: NCT03506022

Intervention type: OTHER
Group type: OTHER
Intervention: standard polysomnography
Description: All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram \[chin\], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
Study: NCT00479557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACC-001 + QS-21
Description: Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACC-001
Description: Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: QS-21
Description: QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Phosphate buffered saline
Description: Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
Study: NCT02376530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrient profiling
Description: Nutrient profiling system will be present during shopping session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrient profiling
Description: Nutrient profiling system will be present during shopping session.
Study: NCT03043560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine
Description: daily for 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo pill daily for 5 weeks